scispace - formally typeset
M

Matti Ojamo

Researcher at National Institutes of Health

Publications -  16
Citations -  326

Matti Ojamo is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Visual impairment & Population. The author has an hindex of 7, co-authored 13 publications receiving 252 citations.

Papers
More filters
Journal ArticleDOI

Inverse association between breast cancer incidence and degree of visual impairment in Finland.

TL;DR: Breast cancer risk decreased by degree of visual impairment (P for trend 0.04) which suggests a dose–response relationship between visible light and breast cancer risk.
Journal ArticleDOI

Visual impairment and cancer: a population-based cohort study in Finland

TL;DR: Cancer incidence among the visually impaired tended to be increased for most cancer types, and attention should be paid to lifestyle factors underlying the observed risk increases, such as unbalanced diet.
Journal ArticleDOI

Does incidence of breast cancer and prostate cancer decrease with increasing degree of visual impairment.

TL;DR: The hypothesis that blind persons are at lower risk of cancer in a follow-up study linking a cohort of 17,557 persons with visual impairment with cancer incidence data of the Finnish Cancer Registry is tested and the result is strongly against the hypothesis of a systemic protective effect related lack of visible light.
Journal ArticleDOI

Low vision status and declining vision decrease Health-Related Quality of Life: Results from a nationwide 11-year follow-up study

TL;DR: In this article, the impact of visual acuity (VA) on health-related quality of life (HRQoL) and the cross-sectional and longitudinal differences in HRQOL during the 11-year follow-up were investigated.

Low vision status and declining vision decrease Health-Related Quality of Life: Results from a nationwide 11-year follow-up study

TL;DR: HRQoL was significantly and meaningfully impaired even before the threshold of severe vision loss or blindness was reached, and the results encourage the improvement of available treatment options aiming to postpone the onset of visual impairment or declining VA, to maintain better quality of life among the population.